Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction.
Yu‐Wen Lin,Chin‐Yu Chen,Jhih‐Yuan Shih,Bor‐Chih Cheng,Ching‐Ping Chang,Mao‐Tsun Lin,Chung‐Han Ho,Zhih‐Cherng Chen,Sudeshna Fisch,Wei‐Ting Chang
DOI: https://doi.org/10.1161/jaha.120.019274
IF: 6.106
2021-03-23
Journal of the American Heart Association
Abstract:Background Mitral regurgitation (MR) is a major contributor for heart failure (HF) and atrial fibrillation. Despite the advancement of MR surgeries, an effective medical therapy to mitigate MR progression is lacking. Sodium glucose cotransporter 2 inhibitors, a new class of antidiabetic drugs, has shown measurable benefits in reduction of HF hospitalization and cardiovascular mortality but the mechanism is unclear. We hypothesized that dapagliflozin (DAPA), a sodium glucose cotransporter 2 inhibitor, can improve cardiac hemodynamics in MR‐induced HF. Methods and Results Using a novel, mini‐invasive technique, we established a MR model in rats, in which MR induced left heart dilatation and functional decline. Half of the rats were randomized to be administered with DAPA at 10 mg/kg per day for 6 weeks. After evaluation of electrocardiography and echocardiography, hemodynamic studies were performed, followed by postmortem tissue analyses. Results showed that DAPA partially rescued MR‐induced impairment including partial restoration of left ventricular ejection fraction and end‐systolic pressure volume relationship. Despite no significant changes in electrocardiography at rest, rats treated with DAPA exhibited lower inducibility and decreased duration of pacing‐induced atrial fibrillation. DAPA also significantly attenuated cardiac fibrosis, cardiac expression of apoptosis, and endoplasmic reticulum stress‐associated proteins. Conclusions DAPA was able to suppress cardiac fibrosis and endoplasmic reticulum stress and improve hemodynamics in an MR‐induced HF rat model. The demonstrated DAPA effect on the heart and its association with key molecular contributors in eliciting its cardio‐protective function, provides a plausible point of DAPA as a potential strategy for MR‐induced HF. Nonstandard Abbreviations and Acronyms A atrial velocity DAPA dapagliflozin E transmitral early filling velocity ER endoplasmic reticulum MR mitral regurgitation Clinical Perspective What Is New? Using a novel and mini‐invasive rat model of mitral regurgitation, we demonstrated a cardio‐protective effect of dapagliflozin on cardiac remodeling. What Are the Clinical Implications? Our findings provide a plausible point of dapagliflozin as a potential strategy for mitral regurgitation‐induced heart failure. Mitral regurgitation (MR) is a valvular heart disease of high prevalence globally and is a known risk factor for atrial fibrillation (AF). 1 , 2 , 3 Although surgical interventions can arrest this pathophysiologic process to the extent of slowing down adverse cardiac remodeling, recurrence of regurgitation and AF correlates with a declining function of both left atrium (LA) and left ventricle (LV) and can lead to heart failure (HF). Given the importance of LA remodeling in disease progression, the cellular and molecular underpinnings of LA can be central to targeting a clinical therapy. Endoplasmic reticulum (ER) is a membrane system that is involved in protein folding, calcium homeostasis, and apoptosis. 4 There are 3 key signaling pathways including ATF6 (activating transcription factor 6), IRE1α (inositol‐requiring protein 1 alpha), and PERK (protein kinase RNA‐like endoplasmic reticulum kinase) that are induced by ER stress. 5 Under stress conditions such as oxidative stress, hypoxia, and calcium depletion, unfolded proteins aggregate and ER dysfunction esnsues. 6 Several reports indicated that ER stress‐associated apoptosis is a contributing factor for myocardial dysfunction and AF development. 6 , 7 , 8 Increased expression of ER stress mediator pro -Abstract Truncated-
cardiac & cardiovascular systems